Overall, although our epigenetic studies covered only 7% of the complete genome, it supports an approach where epigenomic data can be used to identify “actionable targets” to treat DBD; changes in protein expression occurring with diabetes that are not normalized by insulin treatment represent the most likely targets for treating pathophysiology associated with hyperglycemic memory (Reddy et al., 2015). Here, INS is linked to diabetes mellitus.